Compare Cheniere Energy (LNG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cheniere Energy vs Spyre Therapeutics Inc. Common Stock — how do they compare? Cheniere Energy trades at $280.53 (market cap $59.26B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Cheniere Energy is far larger — about 7.9× Spyre Therapeutics Inc. Common Stock's market cap, and Cheniere Energy pays a 0.77% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cheniere Energy for 12 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LNG | SYRE | |
|---|---|---|
Market Cap | $59.26B | $7.52B |
Volume | 1,056,751 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $296.91 | $108.92 |
52-Week Low | $188.83 | $22.18 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $84.72B | $6.52B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cheniere Energy (LNG) trades at $286.92, up 1.57% on the day, with a bullish technical signal from moving averages. The stock exhibits strong profitability with a 45.23% ROE and 13.57% net income margin, though Q1 2026 earnings missed expectations. Recent news highlights the company's long-term growth through a 22-year LNG supply deal with Petrobras, supporting its position in the energy sector.
The outlook is positive with a consensus price target of $307.44, representing 7.2% upside potential. Risks include earnings volatility and capital expenditure demands from growth projects. Analyst sentiment is overwhelmingly bullish with 92.59% buy ratings, but investors should monitor execution on expansion initiatives and energy market dynamics.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cheniere Energy
Cheniere Energy produces, liquefies, and exports natural gas as liquefied natural gas, or LNG. It operates large-scale LNG infrastructure along the U.S. Gulf Coast.
Read more on LNG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
